#USA #Biologics #Beverly, Massachusetts #Akston #Veterinarians

Akston's Leadership Expansion

In an inspiring move towards advancing pet healthcare, Akston recently announced the addition of two highly qualified veterinarians to its leadership team. Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM-CA, and Kristina Kalevas Camp, DVM, PhD, have been appointed to drive the company's innovative pipeline of biologics aimed at tackling significant health challenges faced by pets, ranging from cancer to obesity.

Enhancing Pet Health Through Biologics

Akston, known as the Biotech Built for Pets, is dedicated to bringing pioneering therapies to the veterinary community. The appointments of Dr. Borgatti and Dr. Camp are expected to enhance the company’s efforts in developing first-in-class biologics—cutting-edge treatments designed to usher in a new era of veterinary medicine.

Dr. Antonella Borgatti takes the role of Director of Regulatory - Biologics, where she will oversee the clinical development of biologics regulated by the USDA. With more than 17 years of expertise in clinical research and oncology, Dr. Borgatti previously contributed significantly to veterinary oncology at the University of Minnesota. Her background includes leading clinical investigations for targeted biological drugs and immunotherapies for incurable tumors in pets. This experience positions her well to ensure that Akston's programs are grounded in veterinary realities, ultimately benefiting both pets and their families.

Meanwhile, Dr. Kristina Camp joins Akston as the Director of Clinical Development - Biologics. She brings a robust background in regulatory affairs and scientific expertise in biologics and vaccines. Dr. Camp’s prior experience with Boehringer Ingelheim, where she managed regulatory efforts for numerous products across various markets, will be invaluable. She will direct the regulatory strategy and ensure compliance for Akston’s innovative biologics aimed at improving treatment quality for pets.

The Road Ahead

The addition of these accomplished veterinarians signals a significant leap forward for Akston as it advances its pipeline of therapies for cancer, chronic pain, dermatitis, and obesity in pets. As stated by Todd Zion, PhD, the co-founder and CEO of Akston, the integration of Dr. Borgatti's and Dr. Camp’s expertise will accelerate the company's vision of delivering biologics that last longer, operate more effectively, and are easier to administer. Their leadership is expected to create meaningful advancements in pet care, setting new standards across the veterinary field.

In particular, Akston's notable projects include a promising PD-L1 targeting protein therapy for canine bladder cancer—a collaboration with Purdue University's College of Veterinary Medicine—and an innovative cancer immunotherapy for dogs with solid tumors. Both projects exemplify the company's commitment to pioneering treatment options that drastically improve the quality of life for pets.

Further, Akston is gearing up for conditional FDA licensure of its anti-cPD-L1 monoclonal antibody candidacy by 2027, with additional biologics in development for chronic pain, dermatitis, and obesity. This strategic expansion not only supports veterinarians but also provides pet owners with effective options that can lead to better health outcomes for their beloved companions.

Conclusion

As Akston continues on its path to revolutionizing pet healthcare, the further integration of expertise through the appointments of Dr. Borgatti and Dr. Camp showcases the company's dedication to innovation in veterinary medicine. Their collective vision and focus on science-driven, real-world solutions will enhance Akston's capabilities, enabling pets to experience healthier and happier lives through advanced medical treatments.